Voyager Therapeutics, a clinical-stage gene therapy company based in Lexington, Massachusetts, focuses on developing treatments for severe neurological diseases, including Alzheimer's and ALS. Founded in 2015, it employs 162 people and utilizes its TRACER AAV platform for therapy development.
Robin Swartz sold 6,950 shares of VYGR on 11 February at $4.45 per share, worth a total of $31K. They now own 102,291 VYGR shares, or a 6% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
